Lifetime overproduction of circulating angiotensin-(1-7) attenuates deoxycorticosterone acetate-salt hypertension-induced cardiac dysfunction and remodeling

Hypertension

Volumn 55, Issue 4, 2010, Pages 889-896

  Santiago, Nívia M ^a   Guimarães, Priscila S ^a   Sirvente, Raquel A ^a   Oliveira, Laser A M ^b   Irigoyen, Maria C ^b,c   Santos, Robson A S ^c   Campagnole Santos, Maria J ^a  

^a Laboratory of Hypertension   (Brazil)

^b FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Angiotensin (1 7); Cardiac function; Cardiac remodeling; Hypertension

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN CONVERTING ENZYME 2; ANGIOTENSIN[1-7]; COLLAGEN TYPE 1; COLLAGEN TYPE 3; DEOXYCORTICOSTERONE ACETATE; HYBRID PROTEIN; MESSENGER RNA; ANGIOTENSIN I; ANGIOTENSIN I (1 7); ANGIOTENSIN I (1-7); DEOXYCORTICOSTERONE; PEPTIDE FRAGMENT;

ANGIOTENSIN BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERIAL PRESSURE; ARTICLE; BLOOD PRESSURE FLUCTUATION; COLLAGEN SYNTHESIS; CONTROLLED STUDY; DIASTOLIC DYSFUNCTION; GENE OVEREXPRESSION; HEART FUNCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE FIBROSIS; HEART PROTECTION; HEART VENTRICLE REMODELING; HYPERTENSION; MALE; NONHUMAN; PEPTIDE SYNTHESIS; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN LOCALIZATION; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SPRAGUE DAWLEY RAT; STRAIN DIFFERENCE; TRANSGENIC RAT; ANALYSIS OF VARIANCE; ANIMAL; BLOOD; GENETICS; HEART FUNCTION TEST; IMMUNOHISTOCHEMISTRY; METABOLISM; PATHOPHYSIOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANALYSIS OF VARIANCE; ANGIOTENSIN I; ANIMALS; COLLAGEN TYPE I; COLLAGEN TYPE III; DESOXYCORTICOSTERONE; HEART FUNCTION TESTS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; IMMUNOHISTOCHEMISTRY; PEPTIDE FRAGMENTS; RATS; RATS, TRANSGENIC; RENIN-ANGIOTENSIN SYSTEM; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; VENTRICULAR REMODELING;

EID: 77950505611     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.110.149815     Document Type: Article

References (42)

1. Santos RAS, Ferreira AJ, Simões e Silva AC. Recent advances in the angiotensin converting enzyme 2-angiotensin (1-7)-Mas axis. Exp Physiol. 2008;93:519-527.
2. Ferrario CM, Trask AJ, Jessup JA. Advances in biochemical and functional roles of angiotensin-converting enzyme 2 and angiotensin-(1-7) in regulation of cardiovascular function. Am J Physiol (Heart Circ Physiol). 2005;289:H2281- H2290.
3. Santos RAS, Ferreira AJ, Pinheiro SV, Sampaio WO, Touyz R, Campagnole-Santos MJ. Angiotensin-(1-7) and its receptor as a potential targets for new cardiovascular drugs. Expert Opin Investig Drugs. 2005; 14:1019-1031.
4. Averill DB, Ishiyama Y, Chappell MC, Ferrario CM. Cardiac angioten-sin-(1-7) in ischemic cardiomyopathy. Circulation. 2003;106:2141-2146.
5. Zisman LS, Meixell GE, Bristow MR, Canver CC. Angiotensin-(1-7) formation in the intact human heart: in vivo dependence on angiotensin II as substrate. Circulation. 2003;108:1679-1681.
6. Huentelman MJ, Grobe JL, Vazquez J, Stewart JM, Mecca AP, Katovich MJ. Protection from angiotensin II induced cardiac hypertrophy and fibrosis by systemic lentiviral delivery of ACE2 in rats. Exp Physiol. 2005;90:783-790.
7. Díez-Freire C, Vázquez J, Correa de Adjounian MF, Ferrari MF, Yuan L, Silver X, Torres R, Raizada MK. ACE2 gene transfer attenuates hypertension-linked pathophysiological changes in the SHR. Physiol Genom. 2006;27:12-19.
8. Crackower MA, Oudit GY, Kozieradzki I, Sarao R, Sun H, Sasaki, Hirsch E, Suzuki A, Shioi T, Irie-Sasaki J, Sah R, Cheng HY, Rybin VO, Lembo G, Fratta L, Oliveira-dos-Santos AJ, Benovic JL, Kahn CR, Izumo S, Steinberg SF, Wymann MP, Backx PH, Penninger JM. Angiotensin-converting enzyme 2 is an essencial regulator of heart function. Nature. 2002;417:822-828.
9. Gurley SB, Allred A, Le TH, Griffiths R, Mao L, Philip N, Haystead TA, Donoghue M, Breitbart RE, Acton SL, Rockman HA, Coffman TM. Altered blood pressure responses and normal cardiac phenotype in ACE2-null mice. J Clin Invest. 2006;116:2218-2225.
10. Ferreira AJ, Santos RAS, Almeida AP. Angiotensin-(1-7) improves the post-ischemic function in isolated perfused rat hearts. Braz J Med Biol Res. 2002;35:1083-1090.
11. Ferreira AJ, Santos RAS, Almeida AP. Angiotensin-(1-7): cardiopro-tective effect in myocardial ischemia/reperfusion. Hypertension. 2001;38: 665-668.
12. Loot AE, Roks AJM, Henning RH, Tio RA, Suurmeijer AJH, Boomsma F, Gilst WH. Angiotensin-(1-7) attenuates the development of heart failure after myocardial infarction in rats. Circulation. 2002;105: 1548-1550.
13. Ferreira AJ, Castro CH, Guatimosim S, Almeida PWM, Gomes ERM, Dias-Peixoto MF, Alves MNM, Fagundes-Moura CR, Rentzsch B, Gava E, Almeida AP, Guimaraes AM, Kitten GT, Reudelhuber T, Bader M, Santos RAS. Attenuation of isoproterenol-induced cardiac fibrosis in transgenic rats harboring an angiotensin-(1-7)-producing fusion protein in the heart. Ther Adv Cardiovasc Dis. In press.
14. Grobe JL, Mecca AP, Mao H, Katovich MJ. Chronic angiotensin-(1-7) prevents cardiac fibrosis in DOCA-salt model of hypertension. Am J Physiol (Heart Circ Physiol). 2006;290:H2417-H2423.
15. Grobe JL, Mecca AP, Lingis M, Shenoy V, Bolton TA, Machado JM. Prevention of angiotensin II-induced cardiac remodeling by angiotensin-(1-7). Am J Physiol (Heart Circ Physiol). 2007;292:H736-H742.
16. Mercure C, Yogi A, Callera GE, Aranha AB, Bader M, Ferreira AJ, Santos RAS, Walther T, Touyz RM, Reudelhuber TL. Angiotensin-(1-7) blunts hypertensive cardiac remodeling by a direct effect on the heart. Circ Res. 2008;103:1-8.
17. Santos RAS, Simões e Silva AC, Maric C, Silva DM, Machado RP, Buhr I, Heringher-Walter S, Pinheiro SVB, Lopes MT, Bader M, Mendes EP, Lemos VS, Campagnole-Santos MJ, Schultheiss, Speth R, Walther T. Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc Natl Acad Sci USA. 2003;100:8258-8263.
18. Castro CH, Santos RA, Ferreira AJ, Bader M, Alenina N, Almeida AP. Evidence for a functional interaction of the angiotensin-(1-7) receptor Mas with AT1 and AT2 receptors in the mouse heart. Hypertension. 2005;46:937-942.
19. Castro CH, Santos RA, Ferreira AJ, Bader M, Alenina N, Almeida AP. Effects of genetic deletion of angiotensin-(1-7) receptor Mas on cardiac function during ischemia/reperfusion in the isolated perfused mouse heart. Life Sci. 2006;80:264-268.
20. Santos RAS, Castro HC, Gava E, Pinheiro SVB, Almeida AP, de Paula RD, Cruz JS, Ramos AS, Rosa KT, Irigoyen MC, Bader M, Alenina N, Kitten G, Ferreira AJ. Impairment of In vitro and in vivo heart function in angiotensin-(1-7) receptor mas knockout mice. Hypertension. 2006;47: 996-1002.
21. Tallant EA, Ferrario CM, Galagher PE. Angiotensin-(1-7) inhibits growth of cardiac myocytes through activation of the MAS receptor. Am J Physiol (Heart Circ Physiol). 2005;1:H1560-H1566.
22. Iwata M, Cowling RT, Gurantz D, Moore C, Zhang S, Yuan JX, Greenberg BH. Angiotensin-(1-7) binds to specific receptors on cardiac fibroblasts to iniciate antifibotic and antitrophic effects. Am J Physiol (Heart Circ Physiol). 2005;289:H2356-H2363.
23. Santos RAS, Ferreira AJ, Nadu AP, Braga ANG, Almeida AP, Campagnole-Santos MJ, Baltatu O, Iliescu R, Reudelhuber TL, Bader M. Expression of an angiotensin-(1-7) producing fusion protein produces cardioprotective effects in rats. Physiol Genom. 2004;17:292-299.
24. Van Kats JP, Methot D, Paradis P, Silversides DW, Reudelhuber TL. Use of a biological peptide pump to study chronic peptide hormone action in transgenic mice: direct and indirect effects of angiotensin II on the heart. J Biol Chem. 2001;276:44012-44017.
25. Yin FC, Spurgeon HA, Rakusan K, Weisfeldt ML, Lakatta EG. Use of tibial length to quantify cardiac hypertrophy: application in the aging rat. Am J Physiol (Heart Circ Physiol). 1982;243:H941-H947.
26. Santos SHS, Fernandes LR, Mario EG, Ferreira AVM, Pôrto ACJ, Alvarez-Leite JL, Botion LM, Bader M, Alenina N, Santos RAS. Mas deficiency in FVB/N mice produces marked changes in lipid and glycemic metabolism. Diabetes. 2008;57:340-347.
27. Campbell DJ, Zeitz CJ, Esler MD, Horowitz JD. Evidence against a major role for angiotensin converting enzyme-related carboxypeptidase (ACE2) in angiotensin peptide metabolism in the human coronary circulation. J Hypertension. 2004;22:1971-1976.
28. Gomes-Filho A, Ferreira AJ, Santos SHS, Neves SR, Silva Camargos ER, Becker LK, Belchior HA, Dias-Peixoto MF, Pinheiro SV, Santos RAS. Selective increase of angiotensin-(1-7) and its receptor in spontaneously hypertensive rat hearts subjected to physical training. Exp Physiol. 2008; 93:589-598.
29. Katz SA, Opsahl JA, Wernsing SE, Forbis LM, Smith J, Heller LJ. Myocardial renin is neither necessary nor sufficient to initiate or maintain ventricular hypertrophy. Am J Physiol (Regul Integr Comp Physiol). 2000;278:R578-R586.
30. Mendes AC, Ferreira AJ, Pinheiro SV, Santos RAS. Chronic infusion of angiotensin-(1-7) reduces heart angiotensin II levels in rats. Regul Pept. 2005;125:29-34.
31. Ishiyama Y, Gallagher PE, Averill DB, Tallant EA, Brosnihan KB, Ferrario CM. Upregulation of angiotensin-converting enzyme 2 after myocardial infarction by blockade of angiotensin II receptors. Hypertension. 2004;43: 970-976.
32. Nadu AP, Ferreira AJ, Reudelhuber TL, Bader M, Santos RAS. The isoproterenol induced increase of cardiac Ang II levels associated with heart hypertrophy is blunted in rats harboring an angiotensin-(1-7)-producing fusion protein [TGR(A1-7)3292] [abstract]. Hypertension. 2006;48:e72.
33. Deddish PA, Marcic B, Jackman HL, Wang HZ, Skidgel AR, Erdos EG. N-domain specific substrate and C-domain inhibition of angiotensin-converting enzyme: angiotensin-(1-7) and Keto-ACE. Hypertension. 1998;31:912-917.
34. Trask AJ, Jessup JA, Chappell MC, Ferrario CM. Angiotensin-(1-12) is an alternate substrate for angiotensin peptide production in the heart. Am J Physiol (Heart Circ Physiol). 2008;294:H2242-H2247.
35. Clark MA, Tallant EA, Diz DI. Downregulation of the AT1A receptor by pharmacologic concentrations of angiotensin-(1-7). J Cardiovasc Pharmacol. 2001;37:437-448.
36. Clark MA, Tallant EA, Tommasi E, Bosch S, Diz DI. Angiotensin-(1-7) reduces renal angiotensin II receptors through a cyclooxygenase-dependent mechanism. J Cardiovasc Pharmacol. 2003;41:276-283.
37. Fareh J, Touyz RM, Schiffrin EL, Thibault G. Cardiac type-1 angiotensin II receptor status in deoxycorticosterone acetate-salt hypertension in rats. Hypertension. 1997;30:1253-1259.
38. Hara K, Kobayashi N, Watanabe S, Tsubokou Y, Matsuoka H. Effects of quinapril on expression of eNOS, ACE, and AT1 receptor in deoxycorticosterone acetate-salt hypertensive rats. Am J Hypertens. 2001;14: 321-330.
39. Gomes ER, Lara AA, Almeida PW, Guimarães D, Resende RR, Campagnole-Santos MJ, Bader M, Santos RA, Guatimosim S. Angioten-sin-(1-7) prevents cardiomyocyte pathological remodeling through a nitric oxide/guanosine 3',5'-Cyclic monophosphate-dependent pathway. Hypertension. 2010;55:153-160.
40. Sampaio WO, Nascimento AA, Santos RAS. Systemic and regional hemodynamics effects of angiotensin-(1-7) in rats. Am J Physiol (Heart Circ Physiol). 2003;284:H1985-H1994.
41. Botelho-Santos GA, Sampaio WO, Reudelhuber TL, Bader M, Campagnole-Santos MJ, Santos RAS. Expression of an angiotensin-(1-7)-producing fusion protein in rats induced marked changes in regional vascular resistance. Am J Physiol (Heart Circ Physiol). 2007;292: H2485-H2490.
42. Benter IF, Yousif MH, Anim JT, Cojocel C, Diz DI. Angiotensin-(1-7) prevents development of severe hypertension and end-organ damage in spontaneously hypertensive rats treated with l-NAME. Am J Physiol (Heart Circ Physiol). 2006;290:H684-H691.